EU clears first drug therapy for rare disease cALD
Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
FDA starts speedy review of Imfinzi in bladder cancer
AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.
FDA nominee Overton dodges questions on Trump influence
Trump's FDA nominee Heidi Overton was quizzed on a range of issues at her Senate hearing, including vaccines, the abortion pill, and agency reforms.
Wnt drug gives MSD first eye disease win after EyeBio deal
MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
Australia starts probe into AI infiltration of Medicare
The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Why Join The PM Society?
The professional organisation for people working in pharmaceutical marketing and healthcare communications, and why it's worth being part of.
Six Questions Shaping the Future of Health Innovation
The DIA-MHRA Global Summit explores six questions shaping the next decade of health innovation.
PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...
Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027
PMi Awards 2026 – The Winners and Highlights
Avalere Health is the night’s most awarded agency - Novo Nordisk, Roche, and The Urology Foundation top the client leaderboard
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.